Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

ValdoxanŽ (agomelatine)

Posted by Sonny Liston on February 8, 2006, at 12:50:22

What are the chances the FDA approving this novel compound for depression?

ValdoxanŽ (agomelatine), the first melatonergic (MT1 and MT2 receptor) agonist antidepressant, is an innovation in the treatment of depression with several advantages over existing treatments according to data presented during the 13th Congress of the Association of European Psychiatrists. Besides being an effective antidepressant, Valdoxan has shown particular advantages in improving the often disrupted sleep patterns of depressed patients, without affecting daytime vigilance.

Valdoxan was discovered and developed by Servier. The drug is currently in Phase III and a registration dossier for an indication in MDD was recently submitted to the European Regulatory Agency (EMEA).

Servier also markets Stablon.

Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post

Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in
This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:Sonny Liston thread:607524
URL: http://www.dr-bob.org/babble/20060205/msgs/607524.html